Food and Drug Administration

Biological Response Modifiers Advisory Committee

October 26, 2001

Slides

A Phase I, Open-Label Clinical Trial of the Safety and Tolerability of Single Escalating Doses of Autologous CD4 T Cells Transduced with VRX496 in HIV-Positive Subjects, Boro Dropulic, PhD, VIRxSYS Corporation   pdf